Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 1
2003 1
2004 1
2005 1
2006 5
2007 6
2008 7
2009 10
2010 17
2011 19
2012 11
2013 7
2014 8
2015 8
2016 10
2017 5
2018 7
2019 4
2020 9
2021 5
2022 3
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

127 results
Results by year
Filters applied: . Clear all
Page 1
ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.
Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S, Papachristou EK, Prada JG, Couturier DL, Kumar S, Kishore K, Chilamakuri CSR, Glont SE, Archer Goode E, Brodie C, Guppy N, Natrajan R, Bruna A, Caldas C, Russell A, Siersbæk R, Yusa K, Chernukhin I, Carroll JS. Nagarajan S, et al. Among authors: natrajan r. Nat Genet. 2020 Feb;52(2):187-197. doi: 10.1038/s41588-019-0541-5. Epub 2020 Jan 6. Nat Genet. 2020. PMID: 31913353 Free PMC article.
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.
Clarke M, Mackay A, Ismer B, Pickles JC, Tatevossian RG, Newman S, Bale TA, Stoler I, Izquierdo E, Temelso S, Carvalho DM, Molinari V, Burford A, Howell L, Virasami A, Fairchild AR, Avery A, Chalker J, Kristiansen M, Haupfear K, Dalton JD, Orisme W, Wen J, Hubank M, Kurian KM, Rowe C, Maybury M, Crosier S, Knipstein J, Schüller U, Kordes U, Kram DE, Snuderl M, Bridges L, Martin AJ, Doey LJ, Al-Sarraj S, Chandler C, Zebian B, Cairns C, Natrajan R, Boult JKR, Robinson SP, Sill M, Dunkel IJ, Gilheeney SW, Rosenblum MK, Hughes D, Proszek PZ, Macdonald TJ, Preusser M, Haberler C, Slavc I, Packer R, Ng HK, Caspi S, Popović M, Faganel Kotnik B, Wood MD, Baird L, Davare MA, Solomon DA, Olsen TK, Brandal P, Farrell M, Cryan JB, Capra M, Karremann M, Schittenhelm J, Schuhmann MU, Ebinger M, Dinjens WNM, Kerl K, Hettmer S, Pietsch T, Andreiuolo F, Driever PH, Korshunov A, Hiddingh L, Worst BC, Sturm D, Zuckermann M, Witt O, Bloom T, Mitchell C, Miele E, Colafati GS, Diomedi-Camassei F, Bailey S, Moore AS, Hassall TEG, Lowis SP, Tsoli M, Cowley MJ, Ziegler DS, Karajannis MA, Aquilina K, Hargrave DR, Carceller F, Marshall LV, von Deimling A, Kramm CM, Pfister SM, Sahm F, Baker SJ, Mastronuzzi A, Carai A, Vinci M, Capper D, Popov S, Ellison DW, Jacques TS, Jones DTW, Jones C. Clarke M, et al. Among authors: natrajan r. Cancer Discov. 2020 Jul;10(7):942-963. doi: 10.1158/2159-8290.CD-19-1030. Epub 2020 Apr 1. Cancer Discov. 2020. PMID: 32238360 Free PMC article.
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS. Yap TA, et al. Among authors: natrajan r. J Clin Oncol. 2020 Sep 20;38(27):3195-3204. doi: 10.1200/JCO.19.02404. Epub 2020 Jun 22. J Clin Oncol. 2020. PMID: 32568634 Free PMC article. Clinical Trial.
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
Banerjee S, Stewart J, Porta N, Toms C, Leary A, Lheureux S, Khalique S, Tai J, Attygalle A, Vroobel K, Lord CJ, Natrajan R, Bliss J. Banerjee S, et al. Among authors: natrajan r. Int J Gynecol Cancer. 2021 Nov;31(11):1471-1475. doi: 10.1136/ijgc-2021-002973. Epub 2021 Sep 13. Int J Gynecol Cancer. 2021. PMID: 34518240 Free PMC article.
Subclonal heterogeneity and evolution in breast cancer.
Mavrommati I, Johnson F, Echeverria GV, Natrajan R. Mavrommati I, et al. Among authors: natrajan r. NPJ Breast Cancer. 2021 Dec 21;7(1):155. doi: 10.1038/s41523-021-00363-0. NPJ Breast Cancer. 2021. PMID: 34934048 Free PMC article. Review.
Translational genomics of ovarian clear cell carcinoma.
Khalique S, Lord CJ, Banerjee S, Natrajan R. Khalique S, et al. Among authors: natrajan r. Semin Cancer Biol. 2020 Apr;61:121-131. doi: 10.1016/j.semcancer.2019.10.025. Epub 2019 Nov 4. Semin Cancer Biol. 2020. PMID: 31698086 Free article. Review.
From integrative genomics to therapeutic targets.
Natrajan R, Wilkerson P. Natrajan R, et al. Cancer Res. 2013 Jun 15;73(12):3483-8. doi: 10.1158/0008-5472.CAN-12-4717. Epub 2013 Jun 5. Cancer Res. 2013. PMID: 23740772 Free PMC article. Review.
Splicing dysregulation as a driver of breast cancer.
Read A, Natrajan R. Read A, et al. Among authors: natrajan r. Endocr Relat Cancer. 2018 Sep;25(9):R467-R478. doi: 10.1530/ERC-18-0068. Epub 2018 May 30. Endocr Relat Cancer. 2018. PMID: 29848666 Free PMC article. Review.
Characterisation of the Stromal Microenvironment in Lobular Breast Cancer.
Gómez-Cuadrado L, Bullock E, Mabruk Z, Zhao H, Souleimanova M, Noer PR, Turnbull AK, Oxvig C, Bertos N, Byron A, Dixon JM, Park M, Haider S, Natrajan R, Sims AH, Brunton VG. Gómez-Cuadrado L, et al. Among authors: natrajan r. Cancers (Basel). 2022 Feb 11;14(4):904. doi: 10.3390/cancers14040904. Cancers (Basel). 2022. PMID: 35205651 Free PMC article.
127 results